RNA sequencing of mesenchymal stem cells reveals a blocking of differentiation and immunomodulatory activities under inflammatory conditions in rheumatoid arthritis patients

Jose Ramon Lamas1, Benjamin Fernandez-Gutierrez1, Arkaitz Mucientes1, Fernando Marco2, Yaiza Lopiz2, Juan Angel Jover1, Lydia Abasolo1 and Luis Rodríguez-Rodríguez1

Abstract

Introduction: Mesenchymal stem cells (MSCs) have the ability to differentiate into different types of cells of the mesenchymal lineage, such as osteocytes, chondrocytes, and adipocytes. It is also known that under inflammatory stimuli or in the appropriate experimental conditions, they can also act as regulators of inflammation. Thus, in addition to their regenerating potential, their interest has been extended to their possible use in cell therapy strategies for treatment of immune disorders.

Objective: To analyze, by RNA-seq analysis, the transcriptome profiling of allogenic MSCs under RA lymphocyte activation.

Methods: We identified the differentially expressed genes in bone marrow mesenchymal stem cells after exposure to an inflammatory environment. The transcriptome profiling was evaluated by means of the precise measurement of transcripts provided by the RNA-Seq technology.

Results: Our results evidenced the existence of blocking of both regenerative (differentiation) and immunomodulatory phenotypes under inflammatory conditions characterized by an upregulation of genes involved in immune processes and a simultaneous downregulation of genes mainly involved in regenerative or cell differentiation functions.

Conclusions: We conclude that the two main functions of MSCs (immunomodulation and differentiation) are blocked, at least while the inflammation is being resolved. Inflammation, at least partially mediated by gamma-interferon, drives MSCs to a cellular distress adopting a defensive state. This knowledge could be of particular interest in cases where the damage to be repaired has an important immune-mediated component.

Keywords: Mesenchymal stem cells, Rheumatoid arthritis, RNA-seq, Immunomodulation
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease with a wide spectrum of clinical manifestations, varying from mild to very severe [1, 2]. In order to prevent serious long-term complications, such as joint destruction, functional loss, and preterm mortality, disease remission is the current treatment goal for this condition [3]. However, most patients do not achieve this state [4, 5], despite the use of new drugs, such as biologic agents. Therefore, new therapies are needed to reduce the burden of this condition.

Bone marrow (BM)-derived mesenchymal stem cells (MSCs) are plastic adherent and self-replicating adult stem/progenitor cells with multipotential capacities. MSCs were initially identified in bone marrow but are present virtually in any tissue. The most common sources, besides bone marrow, are adipose tissue, umbilical cord and cord blood, synovial tissue, and dental pulp [6].

MSCs can be easily isolated and are capable to undergo osteogenic, chondrogenic, and adipogenic differentiation in vitro. More recently, it has been also described in vitro the potential of MSCs to interact with immune cells and display immunomodulatory and anti-inflammatory properties. Thus, the use of MSCs as therapeutic agents has been expanded offering new perspectives beyond their regenerative potential becoming optimal candidates for the treatment of immune-mediated diseases [6].

Interactions between MSCs and immune cells are characterized by the existence of a bi-directional crosstalk which influences the final outcome. It is mediated by a combination of cell-to-cell interactions and by paracrine secretion of different soluble factors [7, 8]. These include the interleukin-10 (IL-10) [9], the inducible nitric oxide synthase (iNOS), the cyclooxygenase-2 (COX-2) [10, 11], the transforming growth factor-β (TGF-β) [12], the prostaglandin E2 (PGE2), the nitric oxide (NO), and the indoleamine 2,3-dioxygenase (IDO), among others [13].

Altogether, these combined effects determine the triggering of several immune functions after stimulation by proinflammatory mediators, including the polarization of macrophage pro-inflammatory phenotype M1 to the immunoregulatory M2 phenotype [14]. M2 polarization, in turn, increases the Th2 response (Treg upregulation, immunosuppression, and tissue remodeling). Additionally, MSCs also can enhance angiogenesis promoting the VEGF and angiopoietin-1 production [15].

We used RNA sequencing (RNA-Seq) as an experimental approach to perform a precise measurement of transcripts generated by BM-MSCs interacting with activated or inactive peripheral blood mononuclear cells (PBMCs); moreover, we classified the highly regulated genes from both groups according to functional gene ontologies (GOs) in order to gain insight into the changes these cells undergo when exposed to an inflammatory environment. This knowledge is fundamental for a better understanding of the biological interactions between MSCs and the immune system and to progress toward clinical application of MSCs in regenerative medicine and cell therapy strategies.

Materials and methods
Patients and donors
Demographic and clinical characteristics BM-MSCs donors and of the RA patients are shown in Additional file 1: Table S1 and Additional file 2: Table S2, respectively.

Bone marrow mesenchymal stem cells
Mesenchymal stem cells (MSCs) were obtained from bone marrow (BM) aspirates collected from the iliac crests of three donors, following informed consent. We included subjects older than 18 years old, with no previous diagnosis of autoimmune disease or lymphoproliferative/neoplastic conditions. Briefly, aspirates were diluted in an equal volume with saline and centrifuged over a Ficoll layer at 2000×g for 20 min. Cellular fraction recovered was washed two times in Dulbecco’s modified Eagles medium (DMEM) (Lonza). The cell pellet obtained was suspended in 5 ml with complete culture medium (DMEM supplemented with 2 mM glutamine, 0.06% penicillin, 0.02% streptomycin, and 10% FBS). Cultures were incubated at 37°C in a 5% CO2 humidified atmosphere in 25-cm² flasks. After several days, non-adherent cells were removed and fresh medium was added. The medium was exchanged every 4 days of culture. When cultured cells reached 80–90% confluence, adherent cells were trypsinized (0.05% trypsin/1.0 mM EDTA), harvested, and expanded in 25-cm² flasks. MSC characterization was performed according to the minimal criteria recommended by the ISCT (International Society for Cellular Therapy) described by Dominici et al [16]. Cells in the fourth passage were used in the experimental analysis.

Bone marrow aspirates and blood were obtained in accordance with Good Clinical Practices and the principles expressed in the Declaration of Helsinki. The study was approved by our institutional Ethics Committee (Comité Ético de Investigación Clínica Hospital Clínico San Carlos—Madrid).

Isolation of PBMCs from RA patients
Five consecutive patients diagnosed with RA according to the 2010 ACR/EULAR criteria, attending the Hospital Rheumatology Outpatient Clinic, were included in this study. Patients were over the age of 18 at disease onset and had no previous history of any other chronic disease such as diabetes, chronic kidney disease, and/or lymphoproliferative/neoplastic conditions. We excluded from the study those patients receiving more than 10 mg/day of prednisone or equivalent, those who had received any intramuscular dose of corticosteroids in the previous 2 months, or those treated with drugs that can affect lymphocyte
In vitro BM-MSC–PBMC co-cultures
BM-MSCs (2 × 10^5 cells) were cultured alone for 24 h in non-treated Falcon 6-well flat bottom plates (Corning) in complete low-glucose DMEM (Lonza Group Ltd., Basel, Switzerland) at 37 °C and 5% CO₂. After this time, the medium was replaced by supplemented RPMI. PBMCs (2 × 10^6 cells) were added to the wells in ratio 1:10 (BM-MSC:PBMCs) mostly based on cellular and cellular membrane size.

In some wells, anti-CD3-/anti-CD28-coated beads (Dynabeads® Human T-Activator; Life Technologies) were also added at a ratio of 1 bead per 4 PBMCs.

Three days after co-culturing, supernatant was collected removing the anti-CD3-/anti-CD28-coated beads as well as PBMCs not attached to the BM-MSCs. Furthermore, those weakly attached to the surface of the BM-MSCs were collected by gently pipetting the bottom of each plate with clean RPMI. CD3/CD28 beads were magnetically removed (following the manufacturer's protocol), and PBMCs were recovered after centrifugation and counted, and their viability was assessed by Trypan blue staining. BM-MSCs were treated with Trypsin/EDTA and the remaining PBMCs attached were removed by using anti-CD45 antibodies conjugated to paramagnetic microbeads (Miltenyi Biotec, Spain). Purified BM-MSCs were stored in RNA protect solution (Qiagen Iberia, Madrid, Spain) at −80 °C.

Bioinformatic analyses
Raw sequence quality control was performed using FastQC [17] (Babraham Bioinformatics). The raw sequence reads (FASTQ format) were aligned to the cDNA sequences of the human GRCh37 reference assembly available in UCSC Genome Browser (http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips/hg19.2bit), using the Rsmbread Bioconductor package v1.20.3 [18], using the default settings, and reporting only uniquely mapped reads.

Read summarization was performed with featureCounts [19], using the in-built gene annotations from the NCBI RefSeq for Hg19, included in the Rsmbread package. Mapped reads for each sample were summarized into the meta-feature “gene,” thus obtaining gene-level expression counts that were used as input for gene expression analysis.

In order to improve the statistical power by decreasing the number of multiple comparisons to adjust for and to reduce the possible bias of very small counts with no biological significance, we removed those genes with low expression according to the number of counts for million mapped reads (CPMs). We set a threshold of at least 1 count per million (CPM), in at least 4 of the 5 active and/or 4 of the 5 resting samples.

To adjust for variable sequencing depths between samples, the raw gene counts were normalized using a weighted trimmed mean of the log expression ratios (Trimmed Mean of M values [TMM] algorithm) as implemented in the edgeR Bioconductor package [20, 21]. A multidimensional scaling (MDS) plot was used as an unsupervised approach to visualize the data structure of the analyzed samples.

Statistical analysis
The edgeR Bioconductor package [20] was used to identify genes that were differentially expressed between BM-MSCs co-cultured with activated or resting PBMCs. Our study design had three experimental factors: the BM-MSC donor (three healthy donors), the PBMCs donors (five RA patients), and the PBMC activation state (two levels: resting or activated). Therefore, this comparison (exposure to resting or activated PBMCs from RA patients) was nested by the RA patient from whom the PBMCs were obtained and, in turn, nested by the BM-MSCs donor (Fig. 1).

Based on this design, we used the following formula:

\[ \sim \text{MSC_ID} + \text{MSC_ID} : \text{RA_ID} + \text{MSC_ID} : \text{Activ} \]

Due to the unbalanced design, we manually edited the matrix generated by this formula, removing those columns containing no information. Differential expression was analyzed using the quasi-likelihood F test [20]. Significant differentially expressed genes (DEGs) were defined as

RNA extraction and processing
Total RNA from BM-MSCs was extracted using the RNeasy Mini Kit (Qiagen Iberia, Madrid, Spain), according to the manufacturer’s protocol. RNA concentration was quantified spectrophotometrically (Nanodrop ND-1000, Wilmington, DE), and its quality and integrity assessed by capillary electrophoresis on an Agilent 2100 Bioanalyzer (Agilent Technologies, Spain). Barcoded cDNA libraries were prepared from poly(A) enriched mRNA using NebNext Ultra Directional RNA Library Prep Kit (New England Biolabs, Spain). Pooled libraries were sequenced on an Illumina NextSeq 500 instrument to generate on average 32.9 million single-end reads of 76 bp length. To avoid a batch effect bias, all samples were run simultaneously twice, and results merged.

Assessment of PBMC RNA contamination
In order to assess the degree of RNA contamination from the PBMCs, different approaches were followed (see Additional file 4).

Activation, such as calcium antagonists or statins. At inclusion, demographic and clinical data were collected, and a fasting venous blood sample was extracted on EDTA as anticoagulant. PBMCs were separated by centrifugation on a Ficoll-Hypaque gradient at 900×g, for 20 min at 25 °C.

In vitro BM-MSC–PBMC co-cultures
BM-MSCs (2 × 10^5 cells) were cultured alone for 24 h in non-treated Falcon® 6-well flat bottom plates (Corning) in complete low-glucose DMEM (Lonza Group Ltd., Basel, Switzerland) at 37 °C and 5% CO₂. After this time, the medium was replaced by supplemented RPMI. PBMCs (2 × 10^6 cells) were added to the wells in ratio 1:10 (BM-MSC:PBMCs) mostly based on cellular and cellular membrane size.

In some wells, anti-CD3-/anti-CD28-coated beads (Dynabeads® Human T-Activator; Life Technologies) were also added at a ratio of 1 bead per 4 PBMCs.

Three days after co-culturing, supernatant was collected removing the anti-CD3-/anti-CD28-coated beads as well as PBMCs not attached to the BM-MSCs. Furthermore, those weakly attached to the surface of the BM-MSCs were collected by gently pipetting the bottom of each plate with clean RPMI. CD3/CD28 beads were magnetically removed (following the manufacturer’s protocol), and PBMCs were recovered after centrifugation and counted, and their viability was assessed by Trypan blue staining. BM-MSCs were treated with Trypsin/EDTA and the remaining PBMCs attached were removed by using anti-CD45 antibodies conjugated to paramagnetic microbeads (Miltenyi Biotec, Spain). Purified BM-MSCs were stored in RNA protect solution (Qiagen Iberia, Madrid, Spain) at −80 °C.

RNA extraction and processing
Total RNA from BM-MSCs was extracted using the RNeasy Mini Kit (Qiagen Iberia, Madrid, Spain), according to the manufacturer’s protocol. RNA concentration was quantified spectrophotometrically (Nanodrop ND-1000, Wilmington, DE), and its quality and integrity assessed by capillary electrophoresis on an Agilent 2100 Bioanalyzer (Agilent Technologies, Spain). Barcoded cDNA libraries were prepared from poly(A) enriched mRNA using NebNext Ultra Directional RNA Library Prep Kit (New England Biolabs, Spain). Pooled libraries were sequenced on an Illumina NextSeq 500 instrument to generate on average 32.9 million single-end reads of 76 bp length. To avoid a batch effect bias, all samples were run simultaneously twice, and results merged.

Assessment of PBMC RNA contamination
In order to assess the degree of RNA contamination from the PBMCs, different approaches were followed (see Additional file 4).
those with a log2 fold change ≥ 2 and a false discovery rate (FDR) of ≤ 1% (adjusted with the Benjamini-Hochberg method [22]).

Quality of RNA extraction
The mean (SD) RNA concentration was 255.9 (147.4) ng/μl for BM-MSCs co-cultured with resting PBMCs and 78.7 (28.5) ng/μl for BM-MSCs co-cultured with activated PBMCs. We used 250 ng of RNA from each sample. All samples had a RNA integrity number of 10.

After sequencing, we generated a total number of unique reads mapped to the human genome between 29.6 and 34.9 million, with a mean (SD) across samples of 32.9 (1.7) millions. These reads were summarized into gene-level expression counts, resulting in a mean (SD) of 23.8 (1.5) million successfully assigned reads [a mean (SD) percentage of 72.2 (1.7)] (Table 3). The difference in the number of reads between BM-MSCs co-cultured with activated or resting PBMCs was not statistically significant (Student’s t test, p = 0.82), nor was the difference in the number of reads among BM-MSC samples regarding the donor (ANOVA p-value = 0.66).

Initial summarization of reads into genes revealed 25,702 metafeatures. Count data was filtered based on the number of CPMs in that particular sample. We set a CPM threshold of 1, which represented a minimum gene count between 22 and 26, depending on the library size. After filtering, 12,821 genes remained. We further removed those genes lacking Gene Symbol identifier (n = 219). Therefore, 12,602 genes were analyzed for differential expression.

The MDS plot clearly distinguishes the transcriptional profiles of those BM-MSCs exposed to resting or activated PBMCs, separated along the first dimension. Furthermore, along the second dimension, a difference between the BM-MSCs from the first donor and those from donors 2 and 3 was observed, regardless the BM-MSCs had been exposed to active or resting PBMCs.

Gene Ontology analysis
To understand the biological impact of the gene expression changes, we performed functional enrichment analysis. Considering that for RNA sequencing data, gene length and read count can introduce biases in the gene ontology (GO) enrichment analysis, we used GOseq [23] in order to minimize this bias. We manually introduced the gene length, based on the data from the inbuilt NCBI RefSeq Hg19 annotation from the Rsubread package. We analyzed separately those genes up- or downregulated, considering significantly enriched those terms with an FDR ≤ 1%. Furthermore, since we expected to observe overlapping themes, we collapsed these terms into “supra-categories.”

Network analysis
To further analyze the biological impact of the DEGs, we created protein-protein interaction networks using the STRING database [24]. In order to assess only those interactions more likely to take place, we used a confidence score cutoff of 900, required experimental evidence in order to consider protein-protein interaction, and used only first-order interactions (meaning only molecules directly interacting with our DEG genes).

We also used the InnateDB [25], another curated database of experimentally verified proteins interactions and signaling pathways involved in the innate immune response.

GBP5 analysis
Co-culture experiments Bone marrow-derived MSCs (BM-MSC) from 2 donors and peripheral blood
lymphocytes (PBL) from 4 donors were co-cultured on transwell 12-well culture plates (#3460, Corning® Transwell®) in RPMI 1640 medium (#BE12-167E, Lonza®) supplemented with 10% FBS and antibiotics at 37 °C in a 5% CO2 atmosphere. In each well, 100,000 MSCs were seeded and then added 800,000 PBLs in the upper chamber. Previously, when needed, PBLs were activated with Dynabeads® Human T-Activator CD3/CD28 for T Cell Expansion and Activation (#11131D, Gibco®). Finally, INF-ϒ was neutralized using anti-INF-ϒ antibody (10 μl/ml, B27, BioLegends®).

Five conditions were analyzed: BM-MSCs with anti-INF-ϒ, BM-MSCs with PBLs, BM-MSCs with PBLs and anti-INF-ϒ antibody, BM-MSCs with activated PBLs, and BM-MSCs with activated PBLs and anti-INF-ϒ antibody.

Quantitative PCR Following 3 days of co-culture, medium and PBL were removed and RNA from MSCs were extracted using a commercial RNA extraction kit (SPEEDTOOLS Total RNA Extraction Kit, #21.212-4210, Biotools®). For cDNA generation, Superscript® VILO® cDNA Synthesis Kit (#11754050, Invitrogen®) was employed. Finally, cDNA was resuspended in 20 μl nuclease-free water and stored at −20 °C until required for PCR. The expression of three genes was quantified with specific TaqMan® assays: 18S (Hs99999901_s1, #4331182), ACTB (Hs99999903_m1, #4453320), and GBP5 (Hs00369472_m1, #4448892). Quantitative PCR was carried out following master mix indications (TaqMan® Fast Advanced Master Mix, #4444557, Applied Biosystems®) on a MasterCycler RealPlex4 PCR System (Eppendorf). A triplicate of each sample was done. Fold change of GBP5 for each condition was calculated via $2^{-\Delta\Delta Ct}$ method.

Results
Differential expression of genes
Based on the thresholds set for fold-change and $p$ value, comparing the transcriptomes of BM-MSCs samples exposed to activated RA PBMCs and exposed to resting RA PBMCs, we observed 847 DEGs in total, with 236 genes downregulated and 611 genes upregulated (Table 1 and Additional file 3: Genes). Of those DEGs, 321 were not expressed in BM-MSCs co-cultured with resting PBMCs, and their expression was induced by exposure to active PBMCs. Conversely, the expression of 87 genes was abrogated after exposure to activated PBMCs. Four hundred thirty-nine genes showed expression in both groups.

Biological interpretation of the differentially expressed genes
Regarding the analysis of up-regulated genes, 960 lacked GO annotation and were excluded from the analysis (47 out of 611 DEGs and 913 out of 11,991 non-DEGs). We observed 764 biological process (BP) GO terms significantly overrepresented, considering a FDR threshold < 1%. The 20 most significant GO terms are shown in Table 2 and Additional file 3: Genes.

| Table 1 Top 20 most significantly differentially expressed genes when comparing the transcriptomes of the bone marrow mesenchymal stem cells (BM-MSCs) exposed to activated peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis patients and BM-MSCs exposed to resting PBMCs from RA patients. Positive logarithm of the fold change (Log2FC) indicates greater expression on BM-MSCs exposed to activated PBMCs |
| Entrez ID | Symbol | Log2FC | FDR |
|-----------|--------|--------|-----|
| 4317      | MMP8   | 11.4   | 3.74E–05 |
| 3620      | IDO1   | 9.8    | 3.74E–05 |
| 115362    | GBP5   | 9.5    | 3.74E–05 |
| 3055      | HCK    | 8.4    | 3.74E–05 |
| 5452      | POU2F2 | 6.5    | 3.74E–05 |
| 1440      | CSF3   | 12.4   | 4.66E–05 |
| 6364      | CCL20  | 9.9    | 7.44E–05 |
| 3553      | IL1B   | 9.7    | 7.44E–05 |
| 84419     | C1orf48| 9.2    | 7.44E–05 |
| 64127     | NOD2   | 9.0    | 7.44E–05 |
| 115361    | GBP4   | 6.5    | 7.44E–05 |
| 272       | AMPD3  | 5.7    | 7.44E–05 |
| 9235      | IL32   | 5.2    | 7.44E–05 |
| 6352      | CCL5   | 8.5    | 9.68E–05 |
| 261729    | STEAP2 | 5.2    | 1.06E–04 |
| 2537      | IFI6   | 4.6    | 1.06E–04 |
| 4939      | OAS2   | 3.7    | 1.08E–04 |
| 2919      | CXCL1  | 10.3   | 1.15E–04 |
| 165904    | XIRP1  | 8.1    | 1.15E–04 |
| 29015     | SLC43A3| 4.8    | 1.15E–04 |
networks in BM-MSCs in response to activated PBMCs. Our DEGs were mapped to two molecular interaction databases: STRING and InnateDB. Regarding the first one, 27 subnetworks with at least 3 nodes were observed. We observed 94 different modules. After Bonferroni correction (threshold \( p \) value = \( 5 \times 10^{-4} \)), 31 remained significant, comprising between 10 and 98 genes each. When enrichment analyses were performed in each of the significant modules, we observed 569 BP GO terms significantly upregulated, considering a FDR \( p \) value < 0.05.

Regarding the second database, first-order interactions returned subnetworks with too many nodes (Subnetwork 1: 5482 nodes, 13,927 edges and 953 seeds). Therefore, in order to reduce the complexity of the network, we used zero-order interactions. We observed 37 different modules. After Bonferroni correction (threshold \( p \) value = \( 1.4 \times 10^{-3} \)), 3 remained significant, comprising between 14 and 30 genes each. When enrichment analyses were performed in each of the significant modules, we observed 152 BP GO terms significantly upregulated, considering a FDR \( p \) value < 0.05.

**GBP5 analysis**

To gain insight into the mechanisms related to these results, we performed transwell co-cultures between PBMCs and MSCs. As we can clearly observe in Fig. 2, GBP5 expression is overrepresented on MSCs in the presence of activated PBMCs and this expression is mediated, at least in part, by IFN-gamma.

**Discussion**

MSCs are considered optimal candidates for their therapeutic application in many of the pathologies affecting the musculoskeletal system, including tendinopathies, bone fractures, or osteoarthritis. The mode of application is usually local (non-systemic) aiming to improve the regeneration of target tissue. How this is achieved depends at least on three alternative mechanisms: (1) through differentiation of the MSCs to the damaged cell type in the tissue; (2) activating endogenous progenitor cells to promote angiogenesis, by means of paracrine secretion of factors; and (3) by controlling and modulating the inflammatory response in order to facilitate reparative processes [26].

In the case of RA, these cells hold a great potential for disease amelioration, either due to their ability to differentiate or induce differentiation of local cells to preserve articular homeostasis, or (and probably much more efficiently) due to their capacity to induce

### Table 2

| Category Term                                      | Genes in category | DEGs in category | \( p \) value | FDR \( p \) value |
|---------------------------------------------------|-------------------|------------------|--------------|------------------|
| GO:0006955 Immune response                        | 1014              | 187              | 6.66E-65     | 1.25E-60         |
| GO:0006952 Defense response                       | 1109              | 192              | 4.23E-62     | 3.98E-58         |
| GO:002376 Immune system process                   | 1669              | 227              | 2.41E-55     | 1.51E-51         |
| GO:0043207 Response to external biotic stimulus   | 571               | 121              | 1.46E-46     | 5.49E-43         |
| GO:0051707 Response to other organism             | 571               | 121              | 1.46E-46     | 5.49E-43         |
| GO:0034097 Response to cytokine                   | 613               | 125              | 2.84E-46     | 8.92E-43         |
| GO:0071345 Cellar response to cytokine stimulus   | 531               | 115              | 3.89E-45     | 1.05E-41         |
| GO:0006907 Response to biotic stimulus            | 595               | 121              | 1.35E-44     | 3.19E-41         |
| GO:0006954 Inflammatory response                  | 366               | 95               | 2.48E-44     | 5.19E-41         |
| GO:0019221 Cytokine-mediated signaling pathway    | 422               | 101              | 1.70E-43     | 3.19E-40         |
| GO:002684 Positive regulation of immune system process | 618          | 117              | 5.97E-40     | 1.02E-36         |
| GO:0050896 Response to stimulus                   | 5154              | 398              | 7.48E-40     | 1.17E-36         |
| GO:002682 Regulation of immune system process     | 979               | 146              | 7.82E-38     | 1.13E-34         |
| GO:000605 Response to external stimulus           | 1588              | 188              | 1.10E-35     | 1.38E-32         |
| GO:0045087 Innate immune response                 | 708               | 119              | 1.70E-35     | 1.99E-32         |
| GO:0034341 Response to interferon-gamma           | 103               | 46               | 3.07E-33     | 3.04E-30         |
| GO:000617 Response to bacterium                   | 298               | 74               | 5.57E-33     | 5.25E-30         |
| GO:0006950 Response to stress                     | 2812              | 260              | 3.03E-32     | 2.72E-29         |
| GO:007154 Cell communication                      | 3731              | 304              | 1.14E-29     | 9.35E-27         |
| GO:0001775 Cell activation                        | 600               | 100              | 1.66E-29     | 1.24E-26         |
immunomodulation in the context of diseases with immunological disturbances [27, 28].

Intravenous treatment with MSCs has demonstrated efficacy in RA both in vivo and in vitro [29, 30]. In this sense, when allogenic MSCs are intravenously infused in RA patients, they interact with RA PBMCs in order to modulate their immune function. On the other hand, the RA PBMCs also interact with those allogenic MSCs inducing cellular changes. These interactions are, at least in part, controlled by the activation state of RA PBMCs [31].

In our study, a clearly different behavior is showed on MSCs depending on the activation state of RA PBMCs. Activated RA PBMCs induce on MSCs a defensive/aggressive status characterized by inflammatory mechanisms. The five genes most upregulated in MSCs by activated PBMCs were MMP8, IDO1, GBP5, HCK, and

Table 3 Top 20 most significantly overrepresented biological process gene ontology terms in downregulated differentially expressed genes when comparing mesenchymal stem cells (MSCs) exposed to activated peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) patients with MSCs exposed to resting PBMCs from RA patients

| Category | Term | Genes in category | DEGs in category | p value | FDR p value |
|----------|------|------------------|------------------|---------|-------------|
| GO:0030198 | Extracellular matrix organization | 280 | 27 | 2.51E−11 | 7.88E−08 |
| GO:0043062 | Extracellular structure organization | 280 | 27 | 2.51E−11 | 7.88E−08 |
| GO:0032501 | Multicellular organismal process | 4070 | 128 | 1.65E−10 | 4.44E−07 |
| GO:0007275 | Multicellular organism development | 3185 | 108 | 3.75E−10 | 7.84E−07 |
| GO:0001501 | Skeletal system development | 357 | 28 | 8.09E−10 | 1.52E−06 |
| GO:0044707 | Single-multicellular organism process | 3819 | 120 | 1.51E−09 | 2.36E−06 |
| GO:0048731 | System development | 2834 | 98 | 1.77E−09 | 2.37E−06 |
| GO:0009688 | Tissue development | 1147 | 54 | 2.54E−09 | 3.19E−06 |
| GO:0048856 | Anatomical structure development | 3356 | 109 | 3.40E−09 | 4.00E−06 |
| GO:0030008 | System process | 810 | 43 | 4.52E−09 | 5.00E−06 |
| GO:0032502 | Developmental process | 3770 | 117 | 7.01E−09 | 7.33E−06 |
| GO:0044767 | Single-organism developmental process | 3721 | 115 | 1.47E−08 | 1.46E−05 |
| GO:0007155 | Cell adhesion | 890 | 44 | 2.26E−08 | 2.09E−05 |
| GO:0022610 | Biological adhesion | 893 | 44 | 2.47E−08 | 2.09E−05 |
| GO:0022617 | Extracellular matrix disassembly | 94 | 13 | 8.97E−08 | 6.49E−05 |
| GO:0048513 | Animal organ development | 1980 | 72 | 1.20E−07 | 8.39E−05 |
| GO:0030574 | Collagen catabolic process | 57 | 10 | 2.43E−07 | 1.63E−04 |
| GO:0044243 | Multicellular organism catabolic process | 60 | 10 | 4.05E−07 | 2.54E−04 |
| GO:0009653 | Anatomical structure morphogenesis | 1891 | 68 | 6.10E−07 | 3.59E−04 |
| GO:0009887 | Organ morphogenesis | 617 | 32 | 1.76E−06 | 9.74E−04 |

Table 4 Supra-categories including the biological process gene ontology terms significantly overrepresented when comparing mesenchymal stem cells (MSCs) exposed to activated peripheral blood mononuclear cells (PBMCs) from rheumatoid arthritis (RA) patients vs. MSCs exposed to activated PBMCs from RA patients

| Supra-category | Number of categories in upregulated genes | Number of categories in downregulated genes |
|----------------|-----------------------------------------|-------------------------------------------|
| Immune system-related | 407 | 2 |
| Signaling-related | 89 | 0 |
| Calcium metabolism-related | 53 | 0 |
| Development-related | 50 | 18 |
| Response to pathogens-related | 45 | 0 |
| Nucleic acids metabolism-related | 18 | 0 |
| Wound repair-related | 12 | 0 |
| Nitric oxide metabolism-related | 6 | 0 |
| Miscellanea | 84 | 6 |
POU2F2. The proteins encoded by these genes are related to inflammation exerting different roles, such as transcriptional activity on immunoglobulin gene promoters (POU2F2/OCT2) [32], tyrosin kinase activity (HCK) [33], interferon-gamma-induced cellular factor (GBP5) [34], modulating T cell behavior (IDO1) [35] or inducing the breakdown of extracellular matrix and tissue remodeling (MMP8 [36]).

The specific significantly overrepresented GO terms were immune response, defense response, immune system process and response to external biotic stimulus. In our view, all these data are the result of cellular distress circumventing other functional mechanisms related to the regenerative process including differentiation and immunomodulation.

Similar results were obtained for genes with the highest number of connections. LYN gene (proto-oncogene, Src family tyrosine kinase) encodes a tyrosine protein kinase (involved in cellular activation) [37]. RPS4Y1 gene encodes the ribosomal protein S4 Y-linked 1, related to cellular energy. GNA15 gene encodes the G protein subunit alpha 15 also related to cellular energy [38]. PSMB10 gene encodes a member of the proteasome B-type family that is induced by interferon-gamma, as it occurs with GBP5 [38]. So, a cellular distress mediated, at least in part by gamma-interferon, would be at the origin of these results. The significant modules from the first subnetwork from the STRING interactive database are also in line with this explanation.

On the other hand, most downregulated genes on MSCs related to contact with activated RA cells were in the field of development and cell differentiation. So, these data again are in the context of cellular distress circumventing other functional mechanisms related to the regenerative process including differentiation and immunomodulation.

**Conclusions**

The two main functions of MSCs (immunomodulation and differentiation) are in standby during the resolution phase of inflammation. At least partially, gamma interferon-mediated inflammation induces in MSCs a cellular distress leading to the adoption of a defensive/aggressive state. Our original approach has permitted to identify both a clue to focus on future treatments and a cytokine functionally implied in our results.

These results probably contraindicate the use of MSC treatment in the context of highly inflammatory environments and indicate the need of other different or additional treatments in these scenarios.

**Additional files**

**Additional file 1:** Table S1. Demographic and clinical characteristics of the bone marrow mesenchymal stem cell donors included in this study. (DOCX 12 kb)

**Additional file 2:** Table S2. Demographic and clinical characteristics of the rheumatoid arthritis patients included in this study. (DOCX 13 kb)
Abbreviations
BM: Bone marrow; COX-2: Cyclooxygenase-2; DEGs: Differentially expressed genes; GNA15: G protein subunit alpha 15; GOs: Gene ontologies; IDO: Indoleamine 2,3-dioxygenase; IL-10: Interleukin-10; INOS: Inducible nitric oxide synthase; MSCs: Mesenchymal stem cells; NO: Nitric oxide; PBMCs: Peripheral blood mononuclear cells; PGE2: Prostaglandin E2; RA: Rheumatoid arthritis; RNA-seq: RNA-sequencing; RP54Y: Ribosomal protein 54 Y-linked 1; TGF-β: Transforming growth factor-β

Funding
This research was funded by Instituto de Salud Carlos III (ISCIII; Ministerio de Ciencia, Innovación y Universidades) [RIER 16/0012/0004] and [PI13/01863] (Co-funded by European Regional Development Fund/European Social Fund) “Investing in your future”). LRR was supported by the Miguel Servet program from ISCIII [CP12/03129].

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Authors’ contributions
JRL was responsible for the design of the study and writing. BFG was responsible for the statistical analysis. LA was responsible for the statistical analysis. AM was responsible for the stem cell maps and institutional affiliations. LRR was responsible for general management and writing. AJ was responsible for the stem cell processing. FM and YL were responsible for the surgery process. AM was responsible for general management. LA was responsible for the statistical analysis. LRR was responsible for general management and statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by our institutional Ethics Committee (Comité Ético de Investigación Clínica Hospital Clínico San Carlos—Madrid).

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), UGC de Reumatología, Hospital Clínico San Carlos, Madrid, Spain. 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), UGC de Traumatología, Hospital Clínico San Carlos, Madrid, Spain.

Received: 6 November 2018 Accepted: 8 April 2019

Published online: 06 May 2019

References
1. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol. 1995; 34(Suppl 2):59–73 [cited 2013 Oct 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8535651.
2. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19:137–46 [cited 2013 Sep 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15588975.
3. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 Update. Arthritis Rheum. 2002;46:328–46 [cited 2012 Sep 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11840435.
4. Sokka T, Hetland ML, Mäkikenttä H, Kautainen H, Hershlev-Petersen K, Luukkainen R, et al. Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008;58:2642–51 [cited 2012 Aug 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18750922.
5. Ma MHY, Scott IC, Kingsley GH, Scott DL. Remission in early rheumatoid arthritis. J Rheumatol. 2010;37:1444–53 [cited 2012 Sep 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20516031.
6. Samonrai RM, Raghunath M, Nurmocore V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;6:2173–85 [cited 2015 Oct 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29076267.
7. Caglioni J, Grande D, Molmenti EP, Miller EJ, Rilo HLR. Immunomodulation by mesenchymal stromal cells and their clinical applications. J stem cell Regen Biol. 2017;3 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29104965.
8. Fontaine MJ, Shih H, Schäfer R, Pitteringer MF. Unraveling the mesenchymal stromal cells’ paracrine immunomodulatory effects. Transfus Med Rev. 2016;30:37–43 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26689863.
9. Qu X, Liu X, Cheng K, Yang R, Zhao R. Mesenchymal stem cells inhibit Th1 cell differentiation by IL-10 secretion. Exp Hematol. 2012;40:761–70 [cited 2012 Dec 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22634932.
10. Kim J-H, Lee Y-T, Hong JM, Hwang Y-I. Suppression of in vitro murine T cell proliferation by human adipose tissue-derived mesenchymal stem cells is dependent mainly on cyclooxygenase-2 expression. Anat Cell Biol. 2013;46:262–71 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23486599.
11. Shin T-H, Kim H-S, Kang T-W, Lee B-C, Lee H-Y, Kim Y-J, et al. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammation activation to alleviate rheumatoid arthritis. Cell Death Dis. 2016;7:29524 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28005072.
12. Niu J, Yue W, Le-Le Z, Bin L, Hu X. Mesenchymal stem cells inhibit T cell activation by releasing TGF-β1 from TGF-β1/GARP complex. Oncotarget. 2017;8:99784–800 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29245940.
13. Ling W, Zhang J, Yuan Z, Ren G, Zhang L, Chen X, et al. Mesenchymal stem cells useIDO to regulate immunity in tumor microenvironment. Cancer Res. 2014;74:1576–87 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24452999.
14. Zheng G, Ge M, Qiu G, Shu Q, Xu J. Mesenchymal stromal cells affect disease outcomes via macrophage polarization. Stem Cells Int. 2015;2015:989473 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26257791.
15. Lü L, Deegan A, Musa F, Xu T, Yang Y. The effects of biometrically conjugated VEGF on osteogenesis and angiogenesis of MSCs (human and rat) and HIV/AIDS co-culture models. Colloids Surf B Biointerfaces. 2018;167:550–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29730577.
16. Dominici M, Le Blanc K, Mueller J, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315–7 Available from: http://www.sciencedirect.com/science/article/pii/S1465399405000817.
17. FastQC: A quality control tool for high throughput sequence data. Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
18. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41.
19. Liao Y, Smyth GK, Shi W. FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:2323–30.
20. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26:139–40.
21. Robinson MD, Oshlack A, Wang E, Sandberg R, Luo S, Khatuwutikul I, et al. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 2010;11:R125 Available from: http://genombiology.biomedcentral.com/articles/10.1186/gb-2010-11-3r25.
22. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:1-2: 279–84.
23. Young MD, Wakefield MJ, Smyth GK, Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010;11:R14 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2878278&tool=pmcentrez&rendertype=abstract.
24. Skałczyk D, Franceschini A, Wyder S, Forundk H, Helder D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25352553.
25. Breuer K, Foroushani AK, Laird MR, Chen C, Sebnaia A, Lo R, et al. InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res. 2013;41:D1228–33 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23180781.

26. Lamas López JR. Regenerative medicine applied to treatment of musculoskeletal diseases. Reumatol Clin. 2017;13:139–40 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24801749.

27. Álvaro-Gracia JM, Jover JA, García-Vicuña R, Carreño L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/Ila clinical trial. Ann Rheum Dis. 2017;76:196–202 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27269294.

28. Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, et al. A long-term follow-up study of allogeneic mesenchymal stem/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus. Stem Cell Reports. 2018;10:139–40 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29478901.

29. Abdelmawgoud H, Saleh A. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Adv Clin Exp Med. 2018;27:873–80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29905411.

30. Park EH, Lim H-S, Lee S, Roh K, Seo K-W, Kang K-S, et al. Intravenous infusion of umbilical cord blood-derived mesenchymal stem cells in rheumatoid arthritis: a phase la clinical trial. Stem Cells Transl Med. 2018;7:636–42 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30112846.

31. Martínez-Peinado P, Pascual-García S, Roche E, Sempere-Ortells JM. Differences of clonogenic mesenchymal stem cells on immunomodulation of lymphocyte subsets. J Immunol Res. 2018;2018:7232717 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30271793.

32. Hodson DJ, Shaffer AL, Xiao W, Wright GW, Schmitz R, Phelan JD, et al. Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2. Proc Natl Acad Sci U S A. 2016;113:2039–46 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26993806.

33. Kelher MR, McLaughlin NJD, Banerjee A, Elzi DJ, Gamboni F, Khan SY, et al. LysoPCs induce Hck- and PKCδ-mediated activation of PKCγ causing p47phox phosphorylation and membrane translocation in neutrophils. J Leukoc Biol. 2017;101:261–73 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27531930.

34. Feng J, Cao Z, Wang L, Wan Y, Peng N, Wang Q, et al. Inducible GBP5 mediates the antiviral response via interferon-related pathways during influenza A virus infection. J Innate Immun. 2017;9:419–35 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28576501.

35. Yu C-P, Fu S-F, Chen X, Ye L, Ye Y, Kong L-D, et al. The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis. Cell Physiol Biochem. 2018;49:134–43 Available from: http://www.ncbi.nlm.nih.gov/pubmed/30134237.

36. Dejonckheere E, Vandembroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev. 2011;22:73–81 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21388856.

37. Vermeren S, Miles K, Chu JY, Salter D, Zamoyska R, Gray M. PTPN22 is a critical regulator of Fcγ receptor-mediated neutrophil activation. J Immunol. 2016;197:4771–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27807193.

38. Andrés O, Kellermann T, López-Giraldéz F, Rozas J, Domingo-Roura X, Bosch M. RPS4Y gene family evolution in primates. BMC Evol Biol. 2008;8:142 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18477388.